KLK3 and benign prostatic hyperplasia: Since our goal was to examine the potential of these microRNAs in the discrimination between benign and malignant prostate tumors, which is a major problem in PCa-related clinical practice, BPH patients were used as a control group, instead of self-reported healthy controls who did not undergo the standard diagnostic procedure for PCa or had a negative PSA testing result.